Minimal Residue Disease Testing Market Scope And Analysis

Report Code : TIPRE00039104
Category : Life Sciences

No. of Pages : 150

Buy Now

Minimal Residue Disease Testing Market Analysis, Size, and Growth (2024-2031)

Buy Now

Minimal Residue Disease Testing Market Report Scope

Report Attribute	Details
Market size in 2023	US$ 3.55 Billion
Market Size by 2031	US$ 8.94 Billion
Global CAGR (2023 - 2031)	12.24%
Historical Data	2021-2022
Forecast period	2024-2031
Segments Covered	By Technique Flow Cytometry PCR NGS By Cancer Type Leukemia Lymphoma Solid Tumors Multiple Myeloma By End User Hospitals Specialty Clinics Diagnostic Laboratories
Regions and Countries Covered	North America US Canada Mexico Asia Pacific China Japan South Korea India Australia Rest of Asia Pacific Europe Germany France UK Italy Russia Rest of Europe Middle East and Africa Saudi Arabia UAE South Africa Rest of Middle East and Africa South and Central America Brazil Argentina Rest of South and Central America
Market leaders and key company profiles	Adaptive Biotechnologies Natera Bio Rad Laboratories F Hoffmann La Roche Ltd Guardant Health LabCorp Sysmex Corporation ARUP Laboratories Invivoscribe Inc NeoGenomics Laboratories Inc

Recent Developments:

Companies operating in the minimal residue disease testing market adopt mergers and acquisitions as key growth strategies. As per company press releases, a few recent market developments are listed below:

In April 2023, Quest Diagnostics acquired Haystack Oncology to expand its oncology portfolio with the inclusion of advanced liquid biopsy technology. This addition allowed Quest to improve personalized cancer treatment by providing tools and other products with highly sensitive diagnostic capabilities.
In April 2023, Integrated DNA Technologies launched the Archer FUSIONPlex Core Solid Tumor Panel. This breakthrough testing solution has been improved and refined to cover a broader range of single nucleotide variants (SNVs) and indel (i.e., insertion, deletion, or insertion and deletion of nucleotides) capabilities or aid cancer research.
In December 2022, Adaptive Biotechnologies launched clonoSEQ for assessing minimal residual disease using circulating tumor DNA (ctDNA) in patients that have diffuse large B-cell lymphoma (DLBCL).
In October 2022, Adaptive Biotechnologies and Epic Systems Corporation partnered for the integration of the clonoSEQ assay into Epic's comprehensive electronic medical record (EMR) system. The clonoSEQ assay was monitored and approved by the US Food and Drug Administration (FDA) to detect minimal residual disease associated with multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and B-cell acute lymphoblastic leukemia (ALL).
In August 2022, Roche launched its first Digital LightCycler System, which is designed to accurately quantify trace quantities of specific RNA and DNA.
In February 2022, Personalis collaborated with Moores Cancer Center to support clinical diagnostic testing in patients with advanced solid tumors and hematologic malignancies. The collaboration focused on conducting studies for the detection of highly sensitive minimal residual disease and cancer recurrence using a newly introduced liquid biopsy assay.